Restorative Dentistry is the best option for all kinds of dental issues

The global Restorative Dentistry Market is anticipated to reach USD 25.9 billion by 2025, growing at a CAGR 6.7%,  according to a new report by Grand View Research, Inc. Growing number of dental practices with shifting trend towards group & corporate dental practices, advent of digital dentistry, increasing demand for cosmetic dentistry & implants, and growth of dental tourism are among the key factors driving market growth.

View Summary Of This Report Click Here: www.goo.gl/3hCbhe

With the growing enrollment of students into dental schools, the number of dental practices are likely to increase over the forecast period. The shifting trend towards group, multi-unit, and corporate dental practices which are foccused on providing high-efficiency, quality care to patients is also likely to bolster the restorative dentistry market. Besides, due to growing consumerism and disposable income amongst patients, the demand for cosmetic dentistry procedures focussed on aesthetics is also rising. These factors are in turn likely to boost the restorative dentistry market over the forecast period.

The advent of digital dentistry with technological advancements in areas such as CAD/CAM systems, intraoral imaging, digital radiography, caries diagnosis, and computer-aided implant dentistry have improved the precision and accuracy of restorations, and contributed to the growth of the restorative dentistry market. The growth of dental tourism especially in emerging economies such as India and China is also likely to drive the restorative dentistry market over the forecast period, especially in Asia Pacific.

Further Key Findings From the Study Suggest:

• Restorative materials accounted for the largest share, by product, in 2016 owing to the extensive usage of these materials in dental practice.
• Dental hospitals & clinics segment is anticipated to dominate the market in the forecast period. The growth of this segment can be attributed to the growing number of dental practices and enrollment into dental courses.
• Asia Pacific restorative dentistry market is expected to grow with the highest CAGR over the forecast period owing to the large population of this region along with rising awareness regarding oral health and growing number of dental colleges in this region.
• Major players of the market include, 3M, Dentsply Sirona, Danaher Corporation, Ivoclar Vivadent AG, GC Corporation, Mitsui Chemicals, Inc., Institut Straumann AG, Zimmer Biomet, Septodont Holding, and COLTENE Holding.

Request For Free Sample: www.goo.gl/zAjUQZ

Rising Cases of Diabetic Retinopathy are Driving the "Intraocular Lenses Market"

The global Intraocular Lenses (IOLs) Market is expected to reach USD 5.54 billion by 2025, according to a new report by Grand View Research, Inc. Factors such as rise in prevalence of cataract, increasing aging population with high risk of developing ocular conditions, and government initiatives focused on reducing instances of preventable blindness are expected to drive the market.

Benefits of premium lenses such as enhanced visualization and patient convenience are boosting their adoption globally, thereby propelling the IOLs market. However, factors such as poor reimbursement schemes for premium lenses and high post-treatment costs are challenging market growth.

View Summary Of This Report Click Here: www.goo.gl/chx6ev

Rise in diabetic population has a direct and positive impact on the demand for IOLs as these patients are more susceptible to ocular conditions such as cataract and glaucoma. Development of novel surgical options available for cataract treatment, such as advanced micro-incision surgery and femtosecond lasers are also expected to fuel the market. On the other hand, post-surgical complications such as refractive defects are expected to moderately limit market growth.

Adoption of premium IOLs is expected to increase in the coming years since they offer benefits such as higher precision, enhanced visualization, and multifocal aperture. The premium lenses segment includes multifocal, toric, and accommodative IOLs. Multifocal lenses are proving to be beneficial to patients since they offer multifocal apertures and resolve issues such as astigmatism and presbyopia. Toric IOLs are used in the treatment of astigmatism and are estimated to replace traditional incision procedures to correct vision impairments resulting from astigmatism.

On the other hand, traditional monofocal intraocular lenses are restricted to a single focal point. They are affordably priced compared to premium lenses and hence their adoption rate among standard cataract patients is higher.

North America dominated the global IOLs market. Factors contributing to its dominance include rising adoption of premium intraocular lenses and increasing number of patients suffering from cataract in the U.S.  Asia Pacific is expected to exhibit the fastest growth rate in the global IOLs market. Increasing awareness regarding advanced surgical options and efforts of government as well as non-government organizations to improve awareness on and availability of affordable eye care are factors boosting the regional market.

Further Key Findings from the Report Suggest:

• Multifocal IOL emerged as the largest product segment as a result of high adoption despite increased prices
• Hospitals accounted for the largest share among end-use segments owing to rise in cataract surgeries in hospitals. It is also expected to grow at the fastest rate
• North America dominated the market with the largest revenue share in 2016 owing to improved awareness about advanced vision impairment treatments and increasing disposable income
• Asia Pacific is projected to witness rapid growth during the forecast period owing to speedy adoption of IOLs and advanced treatments for vision repair
• Key players including Johnson & Johnson; Alcon, Inc. (Novartis AG); Valeant Pharmaceuticals International, Inc.; EyeKon Medical, Inc.; Carl Zeiss Meditec AG; Rayner; Lenstec, Inc.; STAAR Surgical; HumanOptics AG; and HOYA GROUP dominated the global IOLs market.

Request For Free Sample: www.goo.gl/EpCfw9

Novel Drug Delivery Systems in Cancer Therapy Market Worth $26.6 Billion By 2025

The global Novel Drug Delivery Systems (NDDS) in cancer therapy market is expected to reach USD 26.61 billion by 2025, according to a new report by Grand View Research, Inc. The market is primarily driven by global rise in incidence of cancer, increase in research activities for developing novel drug delivery technologies, and availability of research funding for ongoing projects. 

Many key players in this market are investing in R&D of novel and advanced products. This can also be attributed to increase in patent expirations. For instance, the R&D expenditure of Celgene Corporation increased from USD 3,697.3 million in 2015 to USD 4,470.1 million in 2016. Increase in R&D spending was directed toward enhancing product pipeline and for regulatory approvals of new products.

View Summary Of This Report Click Here: www.goo.gl/JWyLDC

In addition, rise in healthcare expenditure for diagnosis and treatment of cancer and awareness about alternative therapies are expected to boost market growth. Improvement in healthcare infrastructure in developing nations and increase in awareness about new treatment methods for cancer are also anticipated to propel the market during the forecast period. 

North America held the largest market share in 2016. Local presence of a large number of manufacturers, ongoing regulatory approvals for new drugs, and availability of research funding for new methods of treatment for this disorder are key factors that can be attributed to this region’s dominance in the global market. However, Asia Pacific is expected to grow at the highest rate during the forecast period. This can be attributed to rise in initiatives that boost cancer research projects, increase in healthcare expenditure for cancer therapy, improvement in healthcare infrastructure, large geriatric population base, and rise in awareness owing to medical conferences and meetings in the region.

Further Key Findings From the Report Suggest:

• The nanoparticles segment held the largest revenue share in 2016 due to increase in funding for research using these particles
• The embolization particles segment is expected to grow at the highest rate during the forecast period owing to higher precision rate and accurate drug delivery
• North America dominated the global market due to presence of a large number of cancer patients and favorable reimbursement scenario
• Some of the key players are Celgene Corporation; Teva Pharmaceutical Industries, Ltd.; GALEN; Shire; Johnson & Johnson Services, Inc.; and Spectrum Pharmaceuticals, Inc.

Request For Free Sample: www.goo.gl/pmFZAh

Breastfeeding Accessories Market is Expected to Grow at a CAGR of 7.9%

The global Breastfeeding Accessories Market is anticipated to reach USD 2.4 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to exhibit lucrative growth during the forecast period, owing to rising consumer awareness about breastfeeding accessories coupled with decreasing infant mortality rates. 

Worldwide declining infant mortality rate is expected to fuel the demand for breastfeeding accessories. For instance, according to statistics provided by the World Health Organization (WHO), the infant mortality-rate has declined from around 63 deaths per 1000 births in 1990 to 32 deaths per 1000 births in 2015, more specifically, decreased from 8.9 million in 1990 to 4.5 million in 2015.

View Summary Of This Report Click Here: www.goo.gl/2tCcNj

Additionally, as per statistics published by the U.S. Centers for Disease Control and Prevention (CDC), the infant mortality-rate in the U.S. declined from 6.86 infant deaths per 1,000 births in the year 2005 to 5.82 in 2014 (15.0% decrease). This decreasing infant mortality rate is expected to grow their population, resulting in growing target customer base for breastfeeding accessories.

Continuous encouragement from various government across the world to breast feed babies up to the age of 6 months coupled with support from international agencies for arranging campaigns in order to increase awareness about breastfeeding are expected to support the breastfeeding accessories market growth. Additionally, rising trend of delayed parenthood after gaining financial security is anticipated to increase the spending on premium baby products, thereby assisting in the growth of this vertical.

Further Key Findings From the Study Suggest:

• The breastfeeding storage & feeding segment held lucrative market share in 2016 and is expected to grow at a significant rate over the forecast period owing to increasing penetration rates for the breastmilk containers, breastmilk storage bags & bottles, and feeding systems, as they are Bisphenol A (BPA) & Benzoyl Peroxide (BPS) free
• The nipple care products segment is expected to be the fastest segment during the forecast period owing to rising demand for nipple shields, nipple puller, nipples & lids from lactating mothers to effectively latch baby on nipples in order to breastfeed efficiently
• North America is expected to dominate the breastfeeding accessories market over the forecast period due to increasing number of working mothers in the U.S., growing awareness about breastfeeding accessories, and improved healthcare infrastructure
• Some of the key players in breastfeeding accessories market are Koninklijke Philips N.V.; Medela LLC; Newell Brands; Ameda; Pigeon Corporation; Nuby; Mayborn USA Inc.; Artsana S.p.A.; Edgewell Personal Care; and Handi-Craft Company.

Request For Free Sample: www.goo.gl/sfrWaa

Treatment of "Bifurcation Lesions" to Become Easier with FDA-approved Advanced Stents

A Bifurcation Lesion is a coronary artery disorder, which involves narrowing occurring adjacent to and/or at the origin of an important side branch. Aging and sedentary lifestyle are leading to greater risks of cardiovascular disorders and thereby, bifurcation lesions. Technological advancements and ongoing clinical trials on devices are paving way for novel balloons and stents. Generally, stent implantation is preferred over balloon angioplasty for treatment of the disorder.

Coronary Vascular Lesions to Maintain Dominance through 2025

Stents and balloons can be used for the treatment of coronary vascular and peripheral vascular lesions. Coronary vascular will continue to command the leading share through 2025. Availability of dedicated devices for coronary bifurcation lesions and rise in number of percutaneous coronary intervention procedures performed every year are contributing to the growth of the segment. Increasing clinical trials and advent of novel products are anticipated to supplement the growth of the segment. 

View Summary Of This Report Click Here: www.goo.gl/1MJJCx

The peripheral vascular segment will progress at a higher growth rate through the same period. Rising occurrence of peripheral arterial diseases (PAD) and increasing awareness regarding their treatment can positively impact the growth of the segment. According to a study by the National Institutes of Health (NIH), one in every 20 Americans above 50 years of age is suffering from PAD. Widening application of available products for bifurcation lesions can also drive the growth of the segment.

Market Insights

As per the findings of Grand View Research Inc., the global bifurcation lesions market is projected to expand at a CAGR of 5.6% from 2017 to 2025. Approval of advanced stents is expected to provide an upthrust to the market. For instance, in March 2017, Tryton Side Branch Stent, a product by Tryton Medical, received approval from the US Food and Drug Administration (FDA), which made it the first such device available in U.S. Advancements in imaging modalities, along with an increase in number of skilled surgeons, can augment the market. North America will hold a prominent position throughout the review period (2014–2025), thanks to commercialization of innovative devices for bifurcation lesions. 

Some of the prominent companies operating in the market are Boston Scientific Corporation; Johnson & Johnson Services, Inc.; Abbott; Terumo Medical Corporation; and Medtronic.

Request For Free Sample: www.goo.gl/ERf3od

"Enteric Disease Testing" to Alleviate Mortality among Humans

Increasing presence of pathogens in the air and rising number of casualties have increased the requirement of timely enteric disease testing in humans. Enteric diseases, resulting in symptoms such as nausea, diarrhea, and vomiting, generally happen due to consumption of contaminated food or water. Such diseases are highly communicable and timely testing can help doctors diagnose the accurate problem and provide early treatment.  

View Summary Of This Report Click Here: www.goo.gl/CX6AWK

Rising Strategic Initiatives from Healthcare Organizations

Generally, there are three different types of enteric diseases: bacterial, viral, and parasitic. In 2016, enteric diseases caused by bacteria dominated the market. Salmonella, C. difficile, Shigella, E. coli, and Campylobacter are few bacteria that can cause enteric diseases. Increasing dependency on fast food and insufficient health awareness among humans is giving rise to bacterial infections. According to World Health Organization (WHO), around 1,72,454 people across the world get infected by cholera, resulting in high mortality rate. To handle the situation, various institutes and organizations in healthcare are taking strategic initiatives by promoting timely testing for such infections through healthcare camps and improving vaccines. For instance, a team of researchers at the University of Buffalo in New York is developing a new vaccine that will eradicate maximum bacteria strains causing pneumonia. Current versions of the vaccine can eradicate only 23 forms of Streptococcus pneumonia, including sepsis and meningitis. This advanced vaccine, on the other hand, can handle 72 forms of bacteria out of 90. 

Market Insights

Growing number of molecular diagnostic centers and advanced diagnostic technologies are expected to boost the global enteric disease testing market. In addition, rising dependency of humans on unhygienic fast food and increasing cases of mortality due to enteric infections can augment market growth. Frequent strategic initiatives taken by various healthcare organizations are likely to help the market reach a value of USD 4.2 billion by 2025, states Grand View Research Inc. in a recent report.

Some of the prominent players in the market are Alere Inc.; Quest Diagnostics; Bio Rad Laboratories; Becton Dickinson and Company; and Cepheid.

Request For Free Sample: www.goo.gl/7S6WnM

Clinical Trials – A Necessity in Evaluating Drug Performance

Clinical Trials play a key role in identifying and monitoring the efficacy and future commoditization of drugs and vaccines. It comprises four phases: Phase I for safety, Phase II for efficacy, Phase III for final testing of safety and efficacy, and Phase IV for product sales studies. Such trials are sometimes regarded with distrust due to underreporting of various cases. But recent policies by various drug regulatory agencies have led to mandatory reporting of such cases. For instance, Pfizer, one of the major pharmaceutical manufacturers, offers compensatory benefits to participants for participating in trials. Difficulty in recruiting participants has led to the outsourcing of this task to contract research organizations (CROs).

View Summary Of This Report Click Here: www.goo.gl/UTsmf8

High Success Rate of Biosimilars

The types of indications that demand the need for clinical trials are oncology, cardiovascular diseases, obesity, diabetes, pain management, autoimmune/inflammation, and central nervous system (CNS) disorders. The oncology segment is set for high growth due to extended healthcare budgets in various countries to prevent the growth of various cancers. Biosimilars are drugs that vary from generics due to their complex chemical structure. Their efficacy in treating cancer has led to growing approval by the U.S. Food and Drug Administration (FDA). An example of this is Amgen and Allergan’s Mvasi, a biosimilar to Roche’s Avastin.

In addition, a clinical trial by Celltrion Healthcare and Pfizer displayed the efficacy of biosimilar Inflectra when switched from Remicade, a biologic drug used for treating Crohn’s disease. Lowered manufacturing cost as well as outsourcing of their production to CROs has culminated in saved expenses for the pharmaceutical sector.

Market Outlook

The global clinical trials market is projected to exceed a market size of USD 65 billion by 2025, according to Grand View Research, Inc. Demand for contract research organizations (CROs), increasing prominence of theranostics, and improvements in technology are factors estimated to drive market growth over the forecast period (2014-2025). Increasing demand for biosimilars and outsourcing of R&D to developing economies is expected to have a major impact on market growth. The contribution of clinical trials toward advanced studies in immune-oncology will be paramount in the forthcoming years. The popularity of smartphones has led to major research organizations using it for digital clinical trials.

Key market players include Quintiles IMS, Charles River Laboratories, Paraxel International Corporation, and SGS SA.

Request For Free Sample: www.goo.gl/DtFmcF

Innovative Drugs, Medical Devices is Expected to Boost Smart Pills Market Over the Forecast Period.

The global Smart Pills Market is expected to reach USD 3.0 billion by 2025 at a CAGR of 15.5% during the forecast period, according to a new report by Grand View Research, Inc. Increase in prevalence of diseases such as colorectal cancer and gastrointestinal disorders, expansion in geographical reach of major players, rising cancer screening awareness programs, and expeditious FDA approvals are prime factors that are expected to drive market growth over the forecast period. 

Smart pills have transformed the landscape of small bowel, colon, and gastrointestinal endoscopy by providing a non-invasive and accurate method for visualizing distal duodenum, jejunum, small bowel, colon, gastrointestinal, and ileum. Smart pills are mostly used for screening and treatment of diseases such as colorectal cancer, gastroparesis, gastric ulcers, and gastroesophageal disorders.

View Summary Of This Report Click Here: www.goo.gl/hZEV1S

Consumers of smart pills mostly include geriatric population, immobile patients, and patients with paralysis. Considering the steady rise in geriatric population around the globe, the demand for advanced medical devices will also increase as they offer a degree of convenience to patients.

Established players in this market are enhancing their portfolio by upgrading existing devices. On the other hand, new players are focused on capturing emerging economies with breakthrough products that are both advanced and affordable.

Further key findings from the report suggest:

• Capsule endoscopy is the largest application segment owing to factors such as growth in cancer screening awareness programs, increase in incidence of Crohn’s disease and bowel cancer, and increase in demand for minimally invasive procedures
• North America is the dominant region with the largest revenue share. Wide availability of products, favorable reimbursement policies, increase in government investments in healthcare, and an overall rise in healthcare expenditure support market growth
• Asia Pacific is expected to witness the fastest growth over the forecast period. Factors such as increase in disposable income, mandatory healthcare insurance, and rise in healthcare expenditure are expected to drive the market
• Commercially available smart pills include PillCam Capsule, ABILIFY MYCITE, CapsoCam, and Olympus Endocapsule
• Key players in the smart pills market include Medtronic, Olympus Corporation, Proteus digital Health, MediSafe, and CapsoVision

Request For Free Sample: www.goo.gl/r6TJS1

Home infusion therapy market: A better alternative toward reducing costly hospital stays

The global Home Infusion Therapy Market is expected to be USD 28.3 billion by 2024, based on a new report by Grand View Research, Inc. Increasing need to contain the soaring healthcare costs has led to a higher preference for home infusion therapies amongst patients requiring long-term care.

View Summary Of This Report Click Here: www.goo.gl/nWcpFE

The growing healthcare expenditure level is a key concern amongst patients and governments worldwide, necessitating the implementation of effective measures to curb these costs. Hence, the home healthcare option serves as a cost-effective alternative to expensive hospital stays, which is expected to serve this market as a high impact rendering driver throughout the forecast period. Moreover, increasing awareness about the high prevalence of hospital-acquired infections is anticipated to accentuate the importance of home healthcare.

Currently, the major chronic diseases, such as cancer, diabetes, respiratory disorders, cardiovascular diseases, and other life threatening diseases, account for 60% of the total death count and 43% of the global disease burden. The administration of medication in the home setting provides several advantages to patients, which include faster recovery, greater comfort, fewer complications, cost savings, and others. This is expected to drive the growth of the market in the near future.

Further Key Findings From The Study Suggest:

• The product segment was dominated by infusion pumps with a market share of around 45.0% in 2015 owing to the greater number of initiatives conducted by the key players pertaining to new product development.
• Needleless connectors are projected to witness the highest CAGR over the forecast period owing to greater benefits associated with their use in comparison to needle connectors.
• Anti-infectives segment contributed to the largest market revenue in 2015. This is mainly due to the fact that it is frequently employed for patients in homecare settings.
• Chemotherapy segment is anticipated to exhibit the highest CAGR of over 9.0% over the forecast period, which is attributable to technological advancements that render their usage convenient.
• Use of injectable drug therapy in endocrinology is also estimated to gain lucrative growth over the forecast period owing to increasing awareness levels of insulin pumps among patients and healthcare providers.
• North America dominated the market in 2015 with revenue of around USD 5.0 billion. Rising government programs and initiatives to promote awareness pertaining to the benefits of home infusion therapy have resulted in the higher revenue generation in this region
• Strategic collaborations, regional expansion efforts, and mergers and acquisitions are some of the foremost strategies adopted by the key players. For instance, in January 2014, Terumo Corporation signed an eight-year agreement to collaboratively market, distribute, and co-brand their peripheral I.V. catheter series with CareFusion Corporation.

Request For Free Sample: www.goo.gl/ibi7sb

Ambulance Services Market Worth $48.9 Billion By 2025

The global Ambulance Services Market is anticipated to reach USD 48.9 billion by 2025, according to a new report by Grand View Research, Inc. Increasing geriatric population prone to cardiovascular diseases, favorable reimbursement policies, rising medical tourism, and increasing number of road accidents are the key factors that are driving the market growth.

View Summary Of This Report Click Here: www.goo.gl/3smfV5

The ambulance services market growth is anticipated to increase due to favorable reimbursement policies in the developed nations. In the U.S., Medicare covers both emergency and non-emergency ambulance services, if it is considered medically necessary and the supplier fulfills Medicare ambulance requirements.

However, Medicare does not pay for the ambulette services. In Victoria, Australia, patients can avail ambulance services by securing a membership with Ambulance Victoria which also protects the patient from the high cost of ambulance services. In Tasmania, the Ambulance Tasmania provides free ambulance services to Tasmanian residents within Tasmania only.

Further Key Findings From the Study Suggest:

• Ground ambulance services accounted for the largest share in 2016 owing to the effectiveness and common usage of these ambulance services.
• Emergency services is anticipated to dominate the market in the forecast period. The growth of this segment can be attributed to the increasing prevalence of cardiovascular diseases.
• Advanced Life Support (ALS) ambulance services is anticipated to dominate the market in the forecast period. The growth of this segment can be attributed to rising dependence on life support services among patient, high number of cardiovascular incidents, and increase in technologically advanced equipment and trained personnel.
• Asia Pacific ambulance services market is expected to grow with the highest CAGR over the forecast period
• Major players of the market include, Envision Healthcare Corporation, London Ambulance Service NHS Trust, BVG India Ltd., America Ambulance Services, Inc., Falck Holding A/S, and Medivic Aviation.

Request For Free Sample: www.goo.gl/oA89bq

Medical Device Outsourcing Market is Dynamic and Highly Competitive

The global Medical Device Outsourcing Market is expected to reach USD 88.2 billion by 2025, according to a new report by Grand View Research, Inc. Rising price competition and rising need for reduction of production cost are the most impact rendering driver of the medical device outsourcing market.

Sharp cutbacks in the public spending in major EU regions and the U.S., is the major issue currently faced by medical devices manufacturers. Increasing profitability pressure and growing competition coupled with high degree of industry maturity is expected to impact growth.

View Summary Of This Report Click Here: www.goo.gl/A6g8uv

The medical device outsourcing market is dynamic and highly competitive. Over the next seven years, the industry is expected to witness significant growth owing to steep decline in duration for product commercialization by companies in order to gain the advantage of being the first mover.

Product design and development services are anticipated to be one of the highly availed services by device manufacturers over the forecast period. By opting for this service, manufacturers are expected to benefit in speeding up the time to market and faster return on investment, thereby supporting growth for this segment.

Further key findings from the study suggest:

• In the services segment, contract manufacturing is anticipated to be the fastest growing and contributes over 19.0% of the revenue share by 2025 owing to complete assistance and assurance to the medical device manufacturers.
• Class II medical devices are expected to grow at the fastest rate and hold the largest share of the medical devices outsourcing market by 2025.
• In the therapeutic segment, cardiology, IVD, and drug delivery are the top performing segments. Rising incidences of cardiac failures, infectious diseases and high research activity in the field of drug delivery are certain vital impact rendering factors.
• Regionally, Asia Pacific is predicted to contribute higher revenue share over the forecast period. Improving healthcare infrastructure, rising disposable income, and growing incidence of conditions such as diabetes within the region are expected to support growth.
• Medical device outsourcing market players include; Daiichi Jitsugyo Co. Ltd., Mitutoyo Corp., Hamilton Company, Cirtec Medical Systems LLC, Kinetic Climax Inc., Creganna Tactx Medical Inc. and Omnica Corp. among others.
• In January 2014, Creganna acquired Tactx Medical Inc. in order to expand their business of providing technologies and services for minimally invasive delivery and access devices

Request For Free Sample: www.goo.gl/RXrJZK

Super Resolution Microscopes Market is Expected to Reach USD 4.8 Billion by 2022

Increasing corporate funding and government support for microscopy, growing demand for nanotechnology and technological advancements are expected to serve this market as high impact rendering drivers. Fluorescence imaging using conventional microscopy has encountered various advances in approximately all the limiting factors from speed to sensitivity. Super resolution microscopes have enabled researchers to visualize uniquely the desired molecular species in three dimensions, cellular environment and also in the live cells.

View Summary Of This Report Click Here: www.goo.gl/B92Vs5

Life science dominated the application segment of the super resolution microscopes market in terms of share in 2014. Super resolution microscopes are considered to be viable external substitutes of electron microscopes as they enable researchers to accurately image biological specimens. Increasing research and development pertaining to the fields of neurology and cell biology is expected to further fuel the growth of this market. Nanotechnology is expected to gain significant market share in the recent years due to the increasing requirement of industrial microscopes with the growing usage of smart phones and electronic components around the globe.

Further key findings from the study suggest:

• STED microscopes are identified as the most lucrative sub-segment of the market. The fact that STED microscopes use de-convolution techniques rather than mathematics based principles for image capturing is the most important driver of this market.
• The PALM and STORM product segments accounted for a significant market share in 2014. Live three-dimensional imaging with 3 to 6 color imaging patterns are expected to gain usage rate over the forecast period.
• North America was the most revenue generating region of the market. The market contributed more than 35.0% of the revenue in 2014. Increasing number of funding programs and growing research and development expenditure in the developed North American economies especially the U.S. is expected to drive regional market growth over the forecast period.
• Asia Pacific is expected to spearhead future market growth. Growing interest of photonics companies and venture capitalists in the field of electronics and life sciences, in order to achieve alternate financing is the most vital growth driver of this market.
• Key players of the super resolution microscopes market include Leica Microsystems, Olympus Corporation, Nikon Corporation, Carl Zeiss and Hitachi High Technologies Corporation.

Request For Free Sample: www.goo.gl/KNswTe

Wide Range of Devices With Quick and Accurate Results is Supporting the Diabetes Devices Market Growth

The global Diabetes Devices Market is expected to reach USD 35.5 billion by the year 2024, according to a new report published by Grand View Research, Inc. Major drivers of the market include the growing number of diabetic patients owing to the sedentary lifestyles and unhealthy food habits. The growing demand for the advanced and minimally invasive, diagnostic as well as monitoring devices is expected to propel the market growth during the forecast period.

View Summary Of This Report Click Here: www.goo.gl/YD3Wuc

The rising awareness with regard to the technologically advanced monitoring tools, such as the continuous glucose monitor, is a crucial factor expected to spur the growth of the market. The demand for affordable monitoring devices in the developed as well as the less-developed countries is expected to propel the market growth of products, such as glucose test strips.

The existence of relatively smooth product approval procedures in most of the developed countries including the U.S and European countries are expected to boost the insulin devices market. The rising popularity of the compact, easy to carry monitoring devices, and the introduction of minimally invasive, highly efficient devices is expected to drive the market growth at a lucrative rate. However, the disparity in the reimbursement policies is primarily challenging the overall growth of this market.

Further key findings from the study suggest:

• The demand for the diabetes devices is expected to surge owing to the factors such as the constantly increasing geriatric population prone to diabetes, the government initiatives taken to support better management of diabetes, and the growing awareness regarding diabetes devices
• In 2015, the test-strips sub-segment captured the largest market share in the blood glucose monitoring and diagnostic devices segment. The insulin pens accounted for the largest share of the insulin delivery devices segment. The global diabetes devices market is expected to reach USD 35.4 billion in 2024.
• The monitoring and diagnostic devices segment captured the largest market share of the overall market in 2015. The segment accounted for around 71% of the total market owing to repeat purchases.
• The monitoring and diagnostic devices segment is expected to maintain its dominance during the forecast period owing to the introduction of technologically advanced products coupled with the high adoption of these products in the near future
• North America captured the largest market share of around 32% in the year 2015. The domination of the market is expected to continue with a CAGR of 5.9%. The growing diabetic population, the availability of technologically advanced devices, and the presence of skilled professionals are the factors contributing to the growth of the market in North America.
• Asia Pacific is the fastest growing segment of the market. Countries, such as China and India are expected to show a swift growth owing to the high prevalence of diabetes, the rising awareness regarding commercially available devices, and the growing disposable income in these countries
• The key players in diabetes devices market include Abbott Laboratories, Inc., Bayer Healthcare AG, Johnson& Johnson, F. Hoffmann La-Roche Ltd., Becton Dickinson and Company, Medtronic, Inc., Novo Nordisk A/S, and Sanofi.

Request For Free Sample: www.goo.gl/ez93De

Smart Syringes Market is Expected to Reach USD 10.2 Billion in 2024

The global Smart Syringes Market is expected to reach USD 10.2 billion in 2024, according to a new report by Grand View Research, Inc. In 2015, Some key factors driving the market include the rise in the patient population, the increasing number of needle stick injuries, and the spread of diseases due to unhygienic injection practices.

View Summary Of This Report Click Here: www.goo.gl/NSXvgR

The injection practices and healthcare delivery standards are not uniform across the globe. The use of disposable syringes has been strongly advocated by various healthcare organizations across different countries; however, adherence to the patient safety guidelines is not adequately implemented in the LMIC (Low and Middle Income Countries). 

As per the WHO records, the re-usage of syringes has boosted the infection cases of Ebola, malaria, Marburg virus, HIV, hepatitis, and other diseases in LMIC; these countries have been suffering with a huge infectious diseases burden due to the high transmission rates of blood-borne virus infections. Increasing awareness regarding the usage of smart syringes with safety mechanisms amongst the patients and the healthcare providers is anticipated to fuel the expansion of the smart syringes market over the forecast period. 

As per the data published by the U.S. Occupational Safety and Health Administration (OSHA), nearly 5.6 million workers in the healthcare sector are at a high risk of occupational exposure to blood-borne pathogens, mainly on account of needle stick injuries and other metal injuries. The data also indicates that on an average 1,000 injuries occur per day in the U.S. hospitals, which translates to 385,000 needle stick and other injuries per year. 

Some previously reported outbreaks due to the re-use of syringes include the following:

In 2007, hepatitis C outbreak in Nevada, U.S.

In 2009, more than 400 people were infected with Hepatitis B in Gujarat, India

In 2014, a group of more than 200 people(children and adults) living near Battambang, Cambodia, tested positive for HIV 

Hence, in order to improve the healthcare outcomes and reduce the burden of infections, the healthcare practitioners and hospitals are expected to adopt the usage of smart syringes,which would significantly boost the smart syringes market over the forecast period.  

Further key findings from the study suggest:

• In 2015, the auto-disable syringes segment dominated the smart syringes market with revenue of over USD 3.0 billion. The established presence of the auto-disable syringes in the market is one of the crucial reasons for its high share.
• The passive safety syringes segment is expected to emerge as the fastest growing market during the forecast period
• North America accounted for the largest share in 2015 on account of very high healthcare standards, the presence of well-developed hospital and primary healthcare networks, high patient awareness, and the rising demand for sophisticated drug delivery techniques.
• Asia Pacific is identified as the most lucrative market. Increase in the disease burden, the rising population levels, and the growing demand for vaccination are the key market drivers in this region. Furthermore, high investments to improve the patient care services and to curb the risk of needle stick infections are expected to spur the smart syringes market over the forecast period.
• Some key players of the market include Medtronic Plc (Covidien), Terumo Medical Corporation, Braun Melsungen AG, Unilife Corporation, Becton, Dickinson and Co., Revolutions Medical Corporation, Baxter International, Inc., Retractable Technologies, Inc., and Smiths Group plc.

Request For Free Sample: www.goo.gl/BdawmX

Mobile Stroke Unit Market Worth $9.4 Million By 2022

Global Mobile Stroke Unit Market is expected to reach USD 9.4million by 2022, according to a new report by Grand View Research Inc.The demand for mobile stroke unit is expected to upsurge owing to increasing demand for specialized emergency rooms on wheel to increase the stroke survival rate. 

The incidence rate of stroke is high owing to the lack of awareness amongpeople related to the primary stroke signs and hence the government of developed economies such as the U.S. has established many initiatives at the national level to address this issue. Some of them are Act FAST, Stroke Training and Awareness Resources (STARS), stroke program, and cryogenic stroke awareness.

View Summary Of This Report Click Here: www.goo.gl/gj71H1

Growing healthcare cost burden has also increased the percentage of research funding for stroke. In April 2015, the Health Economics Research Centre at Oxford University compared the research spending for stroke from 2008 to 2012. The result established the fact that the percentage of stroke research funding had increased from 1% to 3%. In 2012, the government and charity spending for stroke in the UK was around USD 4.14 billion. 

Stroke primarily occurs owing to obesity, high blood pressure, cholesterol, and smoking habits. 87% of the stroke is ischemic in nature due to the artery blockage in high blood pressure patients. Obesity leads to difficulty in blood circulation as the body has high fat. 

Further key findings from the report suggest: 

• The U.S. is the most potential market owing to increasedstroke research funding and programs undertaken to increase awareness and high penetration of telemedicine technology. In 2011, the U.S. government spent over USD 302 million for stroke research to prevent the primary signs of stroke such as atrial fibrillation and molecules discovery to treat them. The January 2015 report released by the American Hospital Association, surveyed that in 2013, 52% of hospitals used Telehealth, while 10% implemented it. Consumers are willing to use the Telehealth services (74%) highlighting the fact that telemedicine is highly adopted in the U.S.
• Germany is another potential market owing to the various research funds by the European Union to undertake cardiac research in relation to atrial fibrillation. The ‘RETRAINER’ project was supported by nine partners from Germany, Italy, Austria, and Switzerland. In March 2003, German competence Network on Atrial Fibrillation (AFNET) was formed to investigate the reason of arrhythmia and improving patient care. The concept of mobilestroke unit originated from Germany, where the University of Saarland placed a portable CT scanner in ambulance along with a neurophysiologist to analyze the survival rate instroke patients. The concept was then revolutionized and the world’s first MSU named STEMO came in to existence.
• The UK experiences around 152,000 stroke cases and an annual healthcare cost of USD 12.73 billion. The increasing concern for the lack of stroke awareness led to the foundation of the Act FAST campaign in February 2009. In February 2015, the NHS Lewisham Clinical Commissioning Group and the Public Health England together supported the Act FAST campaign highlighting the common signs of mini-strokes and strokes. After the inception of this program, 38,600 people have additionally gone to hospitals calling 999, the emergency number.
• Manufacturers are also conducting collaborative exercises to study the effect of pre-hospitalization treatment against hospital stroke treatment. In July 2012, Neurologica Corporation and Meytec partnered to develop world’s first comprehensive mobile stroke ambulance. VIMED STEMO combines Meytec’s telemedicine technology with Neurologica’s CT scanner. The state-of-the-art CereTomallows real time imaging, thus reducing the treatment. To address increasing healthcare cost burden, the European nation funded a robotic project to speed up stroke rehabilitation.
• Some key players of MSTUs market includeMeytec, Nueurologica Corporation, Excellance, Frazer, and Falck.

Request For Free Sample: www.goo.gl/3UGK1Q

Assisted Walking Device Market To Reach $2 Billion By 2024

The global Assisted Walking Device Market is expected to reach over USD 2.0 billion by 2024 according to a new report by Grand View Research, Inc. The high market growth is anticipated onaccount of the steep rise in the geriatric population, high prevalence of chronic conditions, such as arthritis, Parkinson’s disease, conversion disorder, tendonitis, and the surging demand for rehabilitation equipment succeeding surgeries. 

Furthermore, apart from the initiatives commenced by the government and private institutions to encourage the use of these assistive walking aids to mobilize the physically-challenged, the technology-oriented innovationsare transforming the current assisted devices,which are expected toserve as catalystsfor the market growthover the forecast period.

View Summary Of This Report Click Here: www.goo.gl/nHTckt

According to the estimates published by the WHO, the elderly population will rise from 900 million to 2.0 billion between 2015 and 2050.The demand for the walking devices is rising amongst thegeriatric population due mainlyto benefits, such as the provision of support, balance, and the subsequent ability to live independently. Moreover, the demand for the rehabilitation equipment is rising as a consequence of thesignificant role they play in bettering the lives of the physically-challenged. 

With the aging population on the rise, the global incidences of arthritis are also escalating in accordance. The estimate stated by the centers of disease control and prevention indicatesthat by 2040, 78 million people will be suffering from arthritis in the U.S.There are over 232 million surgeries performed per year, whichreflects the high demand for the assistive walking devices as a part of the post-surgery rehabilitation programs.

The key players are actively participating in the development of novel walking devices that will create a considerable impact on the quality and durability of the devices thereby influencing market growth.The government organizations and private institutions implement various laws and policies for theassisted devices commercially available to the physicallydisabled people in order to increase their accessibility. Varied government-led programs are specifically directed toward financially assisting individuals in purchasing mobility aids in several countries, such as India, Canada, and Australia.  

Further key findings from the study suggest:

• In 2015, walkers accounted for the highest revenue share of 31.65%. The advantages related to the use of walkers over other walking devices, which include the improved ability to walk independently and safely, decreased pain and discomfort while walking, and the provision of wider support as compared to in other walking devices, and the high weight bearing capacity serve as major reasons resulting in the sizeable revenue share.
• The demand is further accentuated due to the incorporation of these walkers in rehabilitation programs that aim to enable physical activityamongst the disabled, rebuilding of muscular strength, and to help attain optimal mobility of muscles.
• The crutches segment is expected to emerge as the fastest growing segment with a CAGR of 10.3% over the forecast period.This rapid growth pace is a result of the high global demand for the crutches as supportive walking devices and as equipment employed to provide rehabilitative care.The crutches minimize the weight-bearing effect on the disabled leg and help improve the balance and stability of the individual while walking.
• In 2015, North America dominated the Assisted Walking Device Market with a revenue share of 39.58% owing to the hike in thegeriatric population, presence of well-developed social and healthcare sectors, technological advancements forwarded by the leadingplayers in this region, and various initiatives commencedby the government and private organizations offering varied supportive servicesfor the benefit of the physically disabled people.
• The Asia Pacific region is anticipated to grow at the maximum CAGR of over 10.7% from the year 2016 to 2024.Increasing public and private healthcare expenditure and the rising disposable incomes of the population are the key factors supporting the growth of the Assisted Walking Device Market in this region over the forecast period.
• The market dynamics indicate the presence of strong competition amongst the key players, such as Carex Health Brands, Inc., Invacare Corporation, Drive medical design and manufacturing, Inc., Sunrise Medical Laboratories, Inc., Electric mobility Euro Ltd., Pride Mobility Products Corporation, Briggs Healthcare Corporation, Graham-Field Health Products, Inc., Nova medical products, and Patterson Medical Holdings, Inc.

Request For Free Sample: www.goo.gl/JUE7c3

Digital Dose Inhaler Market To Reach $3.56 Billion By 2024

The global Digital Dose Inhaler Market is anticipated to reach a value of USD 3.56 billion by 2024, according to a new report by Grand View Research, Inc. The key factors contributing to the lucrative growth of this market include the continually increasing elderly population and the surging prevalence of chronic respiratory diseases.

As a result of impactful economic developments in the fast emerging countries, such as China, India, Brazil, Philippines, and others, there has been growth in the per capita income, which is thus expected to influence the demand for the technologically advanced respiratory devices. Moreover, these technology-enabled respiratory devices are greatly sought after among the pediatric and the geriatric population so as to improve the patient medication compliance, dose tracking, and to enhance patient-healthcare practitioner connectivity that would enable real-time tracking of healthcare data; these serve as high impact rendering factors, significantly driving the market growth in the next nine years.

View Summary Of This Report Click Here: www.goo.gl/TET6px

In order to cater to the unmet needs of the target population, the vendors are expanding their production units and in addition, targeting the niche areas where the prevalence of chronic lung diseases and asthma are on the rise, such as Asia Pacific and MEA regions, to ensure long-term growth and profitability. Therefore, the aforementioned, business expansion trends are expected to boost the usage rates of the digital dose inhalers over the forecast period.

Additionally, favorable government initiatives, such as the introduction of Fixed Dose Combination (FDC), advanced by the U.S. FDA, fast increasing adoption of generic drugs, and the growing demand for digital health platforms are the identified crucial determinants influencing the rapid uptake of these digital inhalers, which is expected to continue in the coming years.

Rapidly increasing geriatric population worldwide in conjunction with the growing prevalence of various chronic respiratory conditions, such as chronic sleep apnea, asthma, COPD, among others negatively impact healthcare system. This would further escalate the demand for innovative respiratory devices thereby encouraging the digital dose inhalers market growth during the forecast period.

Further key findings from the study suggest:

• In 2015, the metered dose inhalers (MDIs) segment accounted for the maximum revenue of USD 563.9 million, mainly on account of the increased preference for MDIs.
• However, the dry powder inhalers (DPIs) segment is expected to emerge as the fastest growing category with a CAGR of 16.9% over the forecast period owing to the growing awareness regarding the adverse effects of chlorofluorocarbons employed as a propellant in the MDIs. Moreover, widespread incidences of drug irritation due to MDI and rising awareness regarding the benefits of using DPIs over MDIs are the leading factors expected to further drive the usage rates of DPIs over the forecast period.
• In 2015, the branded medication respiratory devices category accounted for the largest market share of USD 747.6 million attributable to the steadily growing need for advanced respiratory drugs and the awareness related to the benefits of combination medication gaining prominence.
• North America held the maximum share of over 38.64% in 2015. This large share is attributed to the presence of several medical device players in this region, such as Johnson & Johnson, Cohera Medical, Inc., Teleflex Medical, Inc., Covidien Plc, and others. There are over 6,000 medical device companies domiciled in this region, which majorly consists of small and medium sized enterprises (SMEs). Moreover, the soaring geriatric population count and the surging prevalence of chronic respiratory diseases, such as asthma and COPD, are few factors, among others, expected to positively reinforce the digital dose inhaler market over the forecast period.
• Some leading players of the market include Glenmark Pharmaceuticals Ltd., Novartis AG, Propeller Health, AstraZeneca Plc, Philips Respironics, Opko Health, Inc., and Teva Pharmaceuticals Industries Ltd.

Request For Free Sample: www.goo.gl/CnBYWb

Capnography Device Market is Expected to Reach USD 1.13 Billion by 2024

The global Capnography Device Market is expected to reach USD 1.13 billion by 2024, according to a new report by Grand View Research, Inc. The introduction of regulatory guidelines for procedural sedation and the growing adoption of capnography in patient monitoring due to higher reliability and efficiency are anticipated to propel the Capnography Device Market over the forecast period. 

In addition, the associated advantages, such as ease-of-usage, minimally invasive nature, and medical efficiency with its usage, are the key growth drivers. Moreover, the rising incidences of respiratory diseases needing continuous patient monitoring are expected to fuel the demand in the coming years.

View Summary Of This Report Click Here: www.goo.gl/TVSmYJ

Furthermore, the increasing focus of industry leaders in the R&D for the development of new-generation capnographs is expected to serve this market with lucrative growth opportunities in the near future. For instance, Oridion’s micro stream technology that helped in minimizing the dispersion of gases in the sampling tube has created a revolution in the Capnography Device Market.  

Further key findings from the study suggest:

• The handheld capnography segment dominated the product market in 2015, owing to its associated benefits such as portability, lightness, ease-of-use, and treatment efficiency 
• On the contrary, multi-parameter capnography devices are expected to grow at a lucrative CAGR of over 18.0% due to their increasing applications in patient monitoring. They are proven to be successful in the detection of ET tube placement verification, breathing irregularities, and monitor procedural sedation. These aforementioned factors attribute towards the growth of the multiparameter segment over the forecast period. 
• Micro stream is identified as the fastest growing technology segment. This can be attributed to the fact that this technology is more effective and easy to incorporate as compared to side stream & main stream capnography. It offers four-hour waveform trending, single-use filters, and a rechargeable battery with eight-hour usage life. These features enable clinicians to treat intubated & non-intubated patients. 
• Ambulatory care centers are expected to grow at a lucrative CAGR during the forecast period. Capnography helps in the early detection of hypoventilation or apnea, which is critical for patients following ambulatory procedures. The aforementioned benefit associated with the adoption of capnography technology is expected to drive the segment growth over the forecast period. 
• Hospitals dominated the end-use segment of the Capnography Device Market owing to the shifting of preference of hospitals from conventional patient monitoring devices to capnography. For instance, Medstar Harbor Hospital in the U.S. adopted capnography to monitor patients following Patient-Controlled Analgesia (PCA) for regulating their post-surgical pain 
• In 2015, North America dominated the overall capnography market at over 55.0% due to the increasing incorporation of capnography in hospitals. Moreover, changes in demographic trends, such as a growing geriatric population and healthcare expenditure, are presumed to boost the industry growth 
• Asia Pacific is anticipated to be growing at the fastest rate over the forecast period owing to high unmet needs for healthcare in the emerging economies such as China & India. Moreover, the increasing prevalence of COPD & asthma in these regions is expected to create future growth opportunities for global leaders in Capnography Device Market 
• Furthermore, the rising medical tourism pertinent to different types of dental surgeries, cosmetic surgeries & cardiac procedures, and the increasing proportion of GDP expenditure on healthcare in growing economies, such as Brazil, are the factors augmenting the capnography equipment industry growth. 
• The key players are now adopting collaborative strategies, such as new product launches and mergers & acquisitions to facilitate the business growth and geographical presence. For instance, in January 2014, Southmedic, Inc. received premarket approval for the C02/02 nasal cannula, in a probe to expand its capnography product portfolio. The introduction of such technologically advanced devices is expected to exert a positive impact on the industry growth during the forecast period.

Request For Free Sample: www.goo.gl/EjKJJf